Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

(2012) Monica Bernal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

(2012) M. L. Huber et al.   JNCI-Journal of the National Cancer Institute

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Alfons JM van den Eertwegh et al.   LANCET ONCOLOGY

MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer

(2012) Barbara Benassi et al.   Cancer Discovery

Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells

(2011) Yu-Wei Chou et al.   CANCER LETTERS

Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

(2011) L. Kretzner et al.   CANCER RESEARCH

 2-Microglobulin Induces Epithelial to Mesenchymal Transition and Confers Cancer Lethality and Bone Metastasis in Human Cancer Cells

(2011) S. Josson et al.   CANCER RESEARCH

Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation

(2011) Sung-Keum Seo et al.   Journal of Thoracic Oncology

Molecular Effects of Genistein on Male Urethral Development

(2011) Ashley E. Ross et al.   JOURNAL OF UROLOGY

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Human Protein Reference Database and Human Proteinpedia as resources for phosphoproteome analysis

(2011) Renu Goel et al.   Molecular BioSystems

Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis

(2011) X. Chen et al.   MOLECULAR CANCER RESEARCH

MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer

(2011) Robert S. Hudson et al.   NUCLEIC ACIDS RESEARCH

Database resources of the National Center for Biotechnology Information

(2011) E. W. Sayers et al.   NUCLEIC ACIDS RESEARCH

Gene expression pathways of high grade localized prostate cancer

(2011) Ashley E. Ross et al.   PROSTATE

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathway Commons, a web resource for biological pathway data

(2010) E. G. Cerami et al.   NUCLEIC ACIDS RESEARCH

Reactome: a database of reactions, pathways and biological processes

(2010) D. Croft et al.   NUCLEIC ACIDS RESEARCH

A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro

(2009) V. C. Daniel et al.   CANCER RESEARCH

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

(2009) D. Mahalingam et al.   CLINICAL CANCER RESEARCH

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

(2009) P. Munster et al.   CLINICAL CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Assessment of the Mitotic Spindle Assembly Checkpoint (SAC) as the Target of Anticancer Therapies

(2009) Victor Bolanos-Garcia   CURRENT CANCER DRUG TARGETS

Histone Deacetylase Inhibitors

(2009) Xujun Ma et al.   DRUGS

Differentiation of a Highly Tumorigenic Basal Cell Compartment in Urothelial Carcinoma

(2009) Xiaobing He et al.   STEM CELLS

An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner

(2008) Eun Joo Noh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors

(2008) M. S.Q. Kortenhorst et al.   CLINICAL CANCER RESEARCH

Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02

(2008) Seth A. Rosenthal et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells

(2008) S. Roy et al.   MOLECULAR CANCER THERAPEUTICS

Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer

(2008) E M Schaeffer et al.   ONCOGENE